These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23334989)

  • 41. Efficacy of chewed vs. crushed lanthanum on phosphorus binding in healthy volunteers.
    How PP; Mason DL; Arruda JA; Lau AH
    Clin Nephrol; 2010 May; 73(5):370-3. PubMed ID: 20420797
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats.
    Bervoets AR; Oste L; Behets GJ; Dams G; Blust R; Marynissen R; Geryl H; De Broe ME; D'Haese PC
    Bone; 2006 Jun; 38(6):803-10. PubMed ID: 16412714
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expanded graphite loaded with lanthanum oxide used as a novel adsorbent for phosphate removal from water: performance and mechanism study.
    Zhang L; Gao Y; Li M; Liu J
    Environ Technol; 2015; 36(5-8):1016-25. PubMed ID: 25284167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets.
    Dodds Ashley ES; Zaas AK; Fang AF; Damle B; Perfect JR
    Antimicrob Agents Chemother; 2007 Mar; 51(3):877-80. PubMed ID: 17145785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone.
    Inaba M; Okuno S; Nagayama H; Yamada S; Ishimura E; Imanishi Y; Shoji S
    J Ren Nutr; 2015 Mar; 25(2):242-6. PubMed ID: 25556148
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Additional reduction in serum phosphorus levels by pulverized lanthanum carbonate chewable in hemodialysis patients.
    Yamashita T; Ogawa T; Takahashi M; Mitsuhashi T; Shizuku J; Takahashi N; Ohba T; Miyajima S; Kabaya T; Otsuka K; Nitta K
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():54-9. PubMed ID: 23586514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lanthanum carbonate--a first line phosphate binder?
    de Freitas D; Donne RL; Hutchison AJ
    Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improving outcomes in hyperphosphataemia.
    De Broe ME; D'Haese PC;
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i14-8. PubMed ID: 15126649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats.
    Robijn S; Vervaet BA; Hoppe B; D'Haese PC; Verhulst A
    J Urol; 2013 May; 189(5):1960-6. PubMed ID: 23228382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
    Spasovski GB; Sikole A; Gelev S; Masin-Spasovska J; Freemont T; Webster I; Gill M; Jones C; De Broe ME; D'Haese PC
    Nephrol Dial Transplant; 2006 Aug; 21(8):2217-24. PubMed ID: 16595583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lanthanum and phosphate: science, policy, and survival.
    Hutchison AJ
    Kidney Int; 2009 Feb; 75(4):355-7. PubMed ID: 19180150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
    Negi S; Shigematsu T
    Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lanthanum carbonate.
    Ryan J
    CANNT J; 2008; 18(1):49-50. PubMed ID: 18435366
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of calcium and lanthanum on phosphate efflux from nonmyelinated nerve fibers.
    Jirounek P; Rouiller M; Jones GJ; Straub RW
    J Membr Biol; 1982; 65(1-2):125-30. PubMed ID: 7057456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Variable efficacy of calcium carbonate tablets.
    Kobrin SM; Goldstein SJ; Shangraw RF; Raja RM
    Am J Kidney Dis; 1989 Dec; 14(6):461-5. PubMed ID: 2596473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
    Wilson R; Zhang P; Smyth M; Pratt R
    Curr Med Res Opin; 2009 Dec; 25(12):3021-8. PubMed ID: 19845495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
    Chan WL; Rounsley K; Chapman E; Collings K; Dale C; De Waal S; Patel V; Tanner J; Turner E; Moore J; Borrows R
    J Ren Nutr; 2010 Jul; 20(4):270-7. PubMed ID: 20362463
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
    Laville M
    Nephrol Ther; 2011 Jun; 7(3):154-61. PubMed ID: 21247818
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phosphate binders.
    Med Lett Drugs Ther; 2006 Feb; 48(1228):15-6. PubMed ID: 16467735
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.